IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Venkatachalapathi Yalamoori

USPTO Granted Patents = 9

Average Co-Inventor Count = 8.3

ph-index = 7

Forward Citations = 170(Granted Patents)


Company Filing History:

goldMedal8 out of 37 
 
Texas Biotechnology Corporation
 patents
silverMedal1 out of 1 
 
Structural Bioinformatics Inc.
 patent

Years Active: 1996-2003

Loading Chart...
9 patents (USPTO):
1. 6541498 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2003-04-01),
2. 6436933 - Inhibitors of anthrax lethal factor activity (2002-08-20),
3. 6376523 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2002-04-23),
4. 6342610 - N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2002-01-29),
5. 6331637 - N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2001-12-18),
6. 6030991 - Benzenesulfonamides and the use thereof to modulate the activity of (2000-02-29),
7. 5594021 - Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that (1997-01-14),
8. 5591761 - Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof (1997-01-07),
9. 5571821 - Sulfonamides and derivatives thereof that modulate the activity of (1996-11-05),

Title: Venkatachalapathi Yalamoori: Innovator in Endothelin Modulation

Introduction

Venkatachalapathi Yalamoori is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the modulation of endothelin activity. With a total of nine patents to his name, Yalamoori's work focuses on developing compounds that can effectively treat endothelin-mediated disorders.

Latest Patents

Yalamoori's latest patents include innovative compounds such as benzenesulfonamides, which are designed to modulate the activity of endothelin peptides. His research provides methods for inhibiting the binding of endothelin peptides to their receptors, as well as increasing the activity of these peptides through the use of sulfonamides. Notably, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides have been highlighted for their potential as endothelin receptor B antagonists. These compounds are particularly promising for treating inflammatory diseases, including asthma, by administering effective amounts that can inhibit or enhance endothelin activity.

Career Highlights

Throughout his career, Yalamoori has worked with notable companies such as Texas Biotechnology Corporation and Structural Bioinformatics Inc. His experience in these organizations has contributed to his expertise in developing therapeutic solutions for complex medical conditions.

Collaborations

Yalamoori has collaborated with esteemed colleagues, including Ming Fai Chan and Bore G Raju. These partnerships have further enriched his research and innovation in the field.

Conclusion

Venkatachalapathi Yalamoori stands out as a key figure in the development of endothelin-modulating compounds. His innovative patents and collaborative efforts continue to pave the way for advancements in treating inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…